WORLDCOM AWARD 2024 in Tokyo Held on Jun 5, 2024
13.6.2024 13:00:00 EEST | Business Wire | Press release
WORLDCOM Public Relations Group held its inaugural "WORLDCOM AWARD 2024 in Tokyo" ceremony in Tokyo, recognizing companies that should be highlighted globally from Japan. The event was organized by AZ WORLDCOM JAPAN Co., Ltd., a member of the WORLDCOM Public Relations Group since 1992. The award ceremony took place on June 5, with representatives from eight distinguished companies receiving accolades from WORLDCOM Public Relations Group's representatives and key executives. Following the ceremony, a reception was held, attended by over 100 participants from 28 countries, celebrating the achievements in grand style.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240609539044/en/
WORLDCOM AWARD 2024 - Ceremony (Photo: Business Wire)
"Each of these companies is truly outstanding and deserves to be showcased to the world. We hope this recognition will further contribute to their continued prosperity." said Stefan Pollack, chairman of the WORLDCOM Public Relations Group and president of the Pollack Group.
“WORLDCOM AWARD 2024 in Tokyo” - Winners
-
Arcuss Japan Inc.
President and CEO: Nobuaki Matsubara
https://www.arcuss-japan.com/ -
HT INTERNATIONAL
President and CEO: Takenori Yamamura
https://www.hti-trade.com/ -
SAKURA Co.,Ltd.
CEO: Kazuyoshi Takahashi
https://www.sakura2012.co.jp/ -
NALU Co.,Ltd.
President and CEO: Tomoko Hori
https://nalu-japan.com/ -
Holon System Co.,Ltd
Chairman: Masahiro Kobayashi
https://www.holon.co.jp/ -
Yokobiki Shutter Co.,Ltd.
CEO: Shinjiro Ichikawa
https://www.yokobiki-shutter.co.jp/ -
Manyou Kensetsu
CEO: Shunichi Sasaki
https://man-you.jp/ -
GATES Inc.
CEO: Yuji Sekino
https://gatestokyo.co.jp/
About the WORLDCOM Public Relations Group
The WORLDCOM Public Relations Group is the world’s leading partnership of independently owned public relations firms, with 143 offices employing some 2,000 staff in 115 cities across six continents. In total, WORLDCOM partners reported combined revenue of US$350+ million last year from 3,034 clients. Established in 1988, the group was formed so that the strongest, most capable independent firms could deliver immediate impact and sustained value through the intelligent use of communications – wherever in the world a client needs support. Partners serve national, international, and multinational clients.
About AZ WORLDCOM Japan Co., Ltd.
AZ WORLDCOM JAPAN Co., Ltd. was founded in 1989, based in Tokyo, Japan, and provides a wide range of PR consulting services for both B2B and B2C clients domestically and internationally. The company has been a member of the WORLDCOM Public Relations Group for over 30 years, contributing significantly to the group's global PR initiatives.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240609539044/en/
Contacts
AZ WORLDCOM JAPAN Co., Ltd.
TEL: +81-3-5005-0281
E-mail: info@azw.co.jp
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom